Your browser is no longer supported. Please, upgrade your browser.
AQST [NASD]
Aquestive Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own2.90% Shs Outstand35.56M Perf Week-3.85%
Market Cap126.20M Forward P/E- EPS next Y-1.28 Insider Trans-6.31% Shs Float34.48M Perf Month-14.70%
Income-53.90M PEG- EPS next Q-0.44 Inst Own45.60% Short Float6.50% Perf Quarter-10.96%
Sales48.20M P/S2.62 EPS this Y36.60% Inst Trans-0.29% Short Ratio3.95 Perf Half Y-39.81%
Book/sh-1.46 P/B- EPS next Y26.00% ROA-90.30% Target Price- Perf Year-42.88%
Cash/sh0.71 P/C4.59 EPS next 5Y- ROE136.30% 52W Range3.10 - 9.47 Perf YTD-39.25%
Dividend- P/FCF- EPS past 5Y-14.30% ROI369.80% 52W High-61.66% Beta-
Dividend %- Quick Ratio2.10 Sales past 5Y76.00% Gross Margin75.00% 52W Low17.06% ATR0.22
Employees187 Current Ratio2.20 Sales Q/Q26.10% Oper. Margin-77.90% RSI (14)51.18 Volatility6.57% 6.28%
OptionableYes Debt/Eq- EPS Q/Q16.20% Profit Margin- Rel Volume6.61 Prev Close3.25
ShortableYes LT Debt/Eq- EarningsAug 03 AMC Payout- Avg Volume567.40K Price3.63
Recom1.80 SMA203.09% SMA50-3.55% SMA200-26.58% Volume1,018,888 Change11.66%
Apr-07-21Resumed RBC Capital Mkts Outperform $7
Apr-22-19Initiated H.C. Wainwright Buy
Jan-03-19Initiated Lake Street Buy $14
Aug-20-18Initiated RBC Capital Mkts Outperform $23
Aug-20-18Initiated JMP Securities Mkt Outperform $29
Aug-03-21 07:25PM  
05:55PM  
Jul-27-21 03:02PM  
Jul-21-21 08:00AM  
Jul-19-21 09:29AM  
Jul-05-21 01:55AM  
Jun-24-21 08:00AM  
Jun-23-21 08:30AM  
Jun-21-21 06:50PM  
09:15AM  
Jun-09-21 08:30AM  
May-11-21 09:27AM  
May-05-21 06:15AM  
May-04-21 08:25PM  
07:53PM  
Apr-30-21 11:37AM  
11:00AM  
09:44AM  
12:40AM  
Apr-29-21 02:27PM  
12:00PM  
11:33AM  
10:14AM  
Apr-28-21 10:27PM  
09:28PM  
12:30PM  
11:33AM  
11:00AM  
10:45AM  
10:00AM  
Apr-27-21 10:37AM  
Apr-26-21 11:40PM  
11:00AM  
11:00AM  
10:35AM  
Apr-25-21 03:05PM  
Apr-24-21 01:47AM  
12:30AM  
Apr-23-21 08:02PM  
01:00PM  
11:00AM  
11:00AM  
09:00AM  
Apr-22-21 10:15PM  
Apr-21-21 10:12PM  
02:59PM  
10:00AM  
09:19AM  
Apr-20-21 11:00AM  
Apr-19-21 10:09PM  
01:00PM  
11:00AM  
Apr-17-21 08:15PM  
Apr-16-21 11:04PM  
02:30PM  
02:25PM  
11:00AM  
Apr-14-21 11:04PM  
04:10PM  
11:00AM  
Apr-13-21 11:00AM  
07:10AM  
Apr-12-21 05:53PM  
01:00PM  
01:00PM  
10:00AM  
Apr-10-21 08:12PM  
05:00PM  
Apr-09-21 01:18PM  
12:00PM  
12:00PM  
Apr-08-21 01:20PM  
10:00AM  
Apr-07-21 02:57PM  
Apr-06-21 04:34PM  
11:00AM  
11:00AM  
04:30AM  
Apr-04-21 03:47AM  
12:30AM  
Apr-03-21 12:48PM  
07:00AM  
Apr-02-21 12:15PM  
Apr-01-21 10:58PM  
07:20PM  
12:30PM  
Mar-31-21 02:20PM  
12:28PM  
02:54AM  
Mar-30-21 01:00PM  
12:30PM  
11:49AM  
11:00AM  
08:00AM  
Mar-29-21 10:27PM  
06:19PM  
01:03PM  
Mar-27-21 09:25PM  
Mar-26-21 05:30PM  
Mar-25-21 12:20PM  
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schobel Alexander MarkChief Innovation/Tech OfficerFeb 10Sale6.7523,460158,355837,000Feb 10 08:17 PM
Schobel Alexander MarkChief Innovation/Tech OfficerFeb 09Sale6.7511,54077,895860,460Feb 10 08:17 PM
Schobel Alexander MarkChief Innovation/Tech OfficerFeb 08Sale6.5040,792265,148872,000Feb 09 04:00 PM
Maxwell John T.SVP-Chief Financial OfficerAug 18Sale8.003,00024,000150,614Aug 19 08:55 AM